Phase I trial and preclinical data of ACT using neoantigen-reactive TIL for patients with advanced epithelial and ICB-resistant solid cancers
2024; Elsevier BV; Volume: 25; Linguagem: Inglês
10.1016/j.iotech.2024.101030
ISSN2590-0188
AutoresJara Palomero, Vladimir Galvao, Immaculada Creus, Júlia Lostes, Miriam Aylagas, A Marín-Bayo, M. Rotxes, Miguel Á. Sanz, Maria Lozano-Rabella, Andrea García-Garijo, Anna Yuste-Estevanez, Daniela Grases, Judit Díaz-Gómez, José María González, José Francisco Navarro, Jared J. Gartner, I Braña, Xenia Villalobos, Neus Bayó-Puxan, J. Jiménez, Asís Palazón, Susana Muñoz, Guillermo Villacampa, Alejandro Piris‐Giménez, Pere Barba, Margarita Codinach, Laura Rodríguez, Sergio Querol, Eva Muñoz‐Couselo, Josep Tabernero, Silvia Martin Lluesma, Alena Gros, Elena Garralda,
Tópico(s)Cancer Immunotherapy and Biomarkers
Referência(s)